AKT1 and non-small cell lung carcinoma: MK‐2206 is a highly selective Akt inhibitor which was evaluated in a phase II trial, in combination with erlotinib, in NSCLC patients who had previously progressed on erlotinib therapy.73 Patients were stratified based on EGFR mutation status.